InflaRx (IFRX) Depreciation & Amortization (CF) (2017 - 2026)
InflaRx (IFRX) posted Depreciation & Amortization (CF) of $102067.9 for Q1 2026, down 3.53% sequentially from $105798.8 in Q4 2025, and down 14.73% YoY from $119705.5 in Q1 2025.
InflaRx (IFRX) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
InflaRx has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $102067.9 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 14.73% year-over-year to $102067.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $454705.6 (down 10.86% YoY) and the FY2025 annual result came in at $473936.6, down 9.74% from the prior year.
- Depreciation & Amortization (CF) eased to $102067.9 in Q1 2026 per IFRX's latest filing, from $105798.8 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $172077.9 in Q1 2022 and troughed at $102067.9 in Q1 2026.
- A 5-year average of $137828.6 and a median of $145824.3 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) dropped 23.6% in 2022, then gained 1.72% in 2023.
- Over 5 years, Depreciation & Amortization (CF) stood at $151276.2 in 2022, then fell by 3.6% to $145824.3 in 2023, then fell by 18.85% to $118333.0 in 2024, then dropped by 10.59% to $105798.8 in 2025, then dropped by 3.53% to $102067.9 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $102067.9, $105798.8, and $116663.5 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102,067.95 |
| Mar 31, 2026 | 102,067.95 |
| Dec 31, 2025 | 105,798.75 |
| Dec 31, 2025 | 105,798.75 |
| Sep 30, 2025 | 116,663.51 |
| Sep 30, 2025 | 116,663.51 |
| Jun 30, 2025 | 130,175.36 |
| Jun 30, 2025 | 130,175.36 |
| Mar 31, 2025 | 119,705.50 |
| Mar 31, 2025 | 119,705.50 |
| Dec 31, 2024 | 118,333.05 |
| Dec 31, 2024 | 118,333.05 |
| Sep 30, 2024 | 122,391.07 |
| Sep 30, 2024 | 122,391.07 |
| Jun 30, 2024 | 149,669.07 |
| Jun 30, 2024 | 149,669.07 |
| Mar 31, 2024 | 134,653.45 |
| Mar 31, 2024 | 134,653.45 |
| Dec 31, 2023 | 145,824.29 |
| Dec 31, 2023 | 145,824.29 |